Navigation Links
Aethlon Medical, Inc. Announces Annual Meeting Results
Date:9/16/2009

SAN DIEGO, Sept. 16 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), reported that at its annual meeting of stockholders completed today in San Diego, California, the stockholders re-elected the incumbent four-person Board of Directors.

Shareholders also:

  • ratified the appointment of Squar, Milner, Peterson, Miranda & Williamson LLP as independent auditors for the fiscal year ending March 31, 2010;
  • approved an increase in authorized shares of its common stock from 100 million shares to 250 million shares.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

Based on the preliminary report from the Inspector of Elections, approximately 82.4 percent of outstanding shares were represented at the meeting and each director received affirmative votes from 99.2 percent or more of the shares voted. Shareholders also ratified Squar, Milner, Peterson, Miranda & Williamson LLP as Aethlon's independent accountants, with affirmative votes from approximately 99.4 percent of the shares that were represented at the meeting. Shareholders ratified the measure to increase the limit on authorized shares, with affirmative votes from approximately 93.0 percent of the shares that were represented at the meeting.

Final vote totals will be included in the company's quarterly report for the fiscal quarter ending September 30, 2009 to be filed with the United States Securities and Exchange Commission.

Jim Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc. said, "We truly appreciate the overwhelming support received from our shareholders."

About Aethlon Medical, Inc.

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

Forward-looking Statements

This release contains forward-looking statements which reflect management's current views of future events and operations including but not limited to estimates of financial performance and cash flows, trends in subscriber preference and engagement and results of marketing strategies. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include the risk of changing economic conditions, the impact of executive management transitions, failure of product demand or market acceptance of both existing and new products and services and the impact of competitive products and pricing. Please see Aethlon Medical, Inc.'s recent filings with the Securities and Exchange Commission for information about these and other risks that may affect the Company. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements speak only as of the date hereof, and Aethlon Medical, Inc. does not undertake to publicly update or revise any of its forward-looking statements, even if experience or future changes show that the indicated results or events will not be realized.

    Contacts:

    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell
    www.redchip.com
    Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
2. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
3. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
4. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. China Sky One Medical, Inc. Appoints New Independent Director
7. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
8. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
9. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
10. China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program
11. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):